Clinical and prognostic value of the C‐Met/HGF signaling pathway in cervical cancer

Aberrant activation of the HGF/c‐Met signalling pathway is reported to be associated with cell proliferation, progression, and metastasis features of several tumor types, including cervical cancer, suggesting that it may be of potential value as a novel therapeutic target. Furthermore, HPV‐positive patients had a higher serum level of HGF or c‐Met protein, compared with HPV‐negative patients. c‐Met or HGF overexpression in lesions of cervical cancer is reported to be related to a poorer prognosis, and hence this may be of value as a prognostic and predictive biomarker. Several approaches have been developed for targeting HGF and/or c‐Met. One of these is crizotinib (a dual c‐Met/ALK inhibitor). This has been approved by FDA for the treatment of lung‐cancer. Further investigations are required to evaluate and optimize the use of c‐Met inhibitors in cervical cancer or parallel targeting signalling pathway associated/activated via MET/HGF pathway. The main aim of current review was to give an overview of the potential of the c‐Met/HGF pathway as a prognostic, or predictive biomarker in cervical cancer.